{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T14:36:26Z","timestamp":1789655786833,"version":"4.0.1"},"reference-count":160,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,1,29]],"date-time":"2018-01-29T00:00:00Z","timestamp":1517184000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1007\/s12185-018-2411-9","type":"journal-article","created":{"date-parts":[[2018,1,29]],"date-time":"2018-01-29T03:52:30Z","timestamp":1517197950000},"page":"5-21","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":67,"title":["\u03b2-Thalassemia intermedia: a comprehensive overview and novel approaches"],"prefix":"10.1007","volume":"108","author":[{"given":"Chingiz","family":"Asadov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zohra","family":"Alimirzoeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tahira","family":"Mammadova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunay","family":"Aliyeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahla","family":"Gafarova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeyhun","family":"Mammadov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,1,29]]},"reference":[{"issue":"Suppl 1","key":"2411_CR1","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/S0268-960X(12)70003-6","volume":"26","author":"DJ Weatherall","year":"2012","unstructured":"Weatherall DJ. The definition and epidemiology of non-transfusion-dependent thalassemia. Blood Rev. 2012;26(Suppl 1):S3\u20136.","journal-title":"Blood Rev"},{"key":"2411_CR2","volume-title":"Guidelines for the management of non-transfusion dependent thalassaemia (NTDT)","year":"2013","unstructured":"Taher AT, Vinchinsky E, Musallam KM, Cappellini MD, Viprakasit V, editors. Guidelines for the management of non-transfusion dependent thalassaemia (NTDT). Nicosa: Thalassaemia International Federation; 2013."},{"issue":"6","key":"2411_CR3","doi-asserted-by":"publisher","first-page":"833","DOI":"10.3324\/haematol.2012.066845","volume":"98","author":"KM Musallam","year":"2013","unstructured":"Musallam KM, Rivella S, Vichinsky E, Rachmilewitz EA. Non-transfusion-dependent thalassemias. Haematologica. 2013;98(6):833\u201344.","journal-title":"Haematologica"},{"issue":"4","key":"2411_CR4","doi-asserted-by":"crossref","first-page":"53","DOI":"10.33590\/emj\/10311793","volume":"1","author":"AA Bazarbachi","year":"2016","unstructured":"Bazarbachi AA, Chaya BF, Moukhadder HM, Taher AT. Non-transfuison-dependent thalassemia: a panoramic survey from pathophysiology to treatment. Eur Med J. 2016;1(4):53\u201361.","journal-title":"Eur Med J"},{"issue":"10","key":"2411_CR5","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1182\/blood-2009-09-243154","volume":"115","author":"AT Taher","year":"2010","unstructured":"Taher AT, Musallam KM, Karimi M, El-Beshlawy A, Belhoul K, Daar S, et al. Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the Optimal Care study. Blood. 2010;115(10):1886\u201392.","journal-title":"Blood"},{"issue":"1","key":"2411_CR6","doi-asserted-by":"publisher","first-page":"5","DOI":"10.4274\/Tjh.2014.0032","volume":"31","author":"A Haddad","year":"2014","unstructured":"Haddad A, Tyan P, Radwan A, Mallat N, Taher A. \u03b2-Thalassemia intermedia: a bird\u2019s-eye view. Turk J Haematol. 2014;31(1):5\u201316.","journal-title":"Turk J Haematol"},{"issue":"7","key":"2411_CR7","doi-asserted-by":"publisher","first-page":"583","DOI":"10.3109\/08880018.2014.937884","volume":"31","author":"M Karimi","year":"2014","unstructured":"Karimi M, Cohan N, De Sanctis V, Mallat NS, Taher A. Guidelines for diagnosis and management of beta-thalassemia intermedia. Pediatr Hematol Oncol. 2014;31(7):583\u201396.","journal-title":"Pediatr Hematol Oncol"},{"issue":"3","key":"2411_CR8","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1046\/j.1365-2141.2003.04769.x","volume":"124","author":"SL Thein","year":"2004","unstructured":"Thein SL. Genetic insights into the clinical diversity of \u03b2-thalassaemia. Br J Haematol. 2004;124(3):264\u201374.","journal-title":"Br J Haematol"},{"issue":"(Database issue","key":"2411_CR9","doi-asserted-by":"publisher","first-page":"D537","DOI":"10.1093\/nar\/gkh006","volume":"32","author":"GP Patrinos","year":"2004","unstructured":"Patrinos GP, Giardine B, Riemer C, Miller W, Chui DH, Anagnou NP, et al. Improvements in the HbVar database of human hemoglobin variants and thalassemia mutations for population and sequence variation studies. Nucleic Acids Res. 2004;32((Database issue)):D537\u201341.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"2411_CR10","first-page":"e2009004","volume":"1","author":"AT Taher","year":"2009","unstructured":"Taher AT, Musallam KM, Cappellini MD. Thalassaemia intermedia: an update. Mediterr J Hematol Infect Dis. 2009;1(1):e2009004.","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"2411_CR11","doi-asserted-by":"publisher","first-page":"291","DOI":"10.3109\/03630269.2013.774283","volume":"37","author":"CD Asadov","year":"2013","unstructured":"Asadov CD, Abdulalimov ER, Mammadova TA, Qafarova SN, Guliyeva YJ, Tuli A, et al. Identification of two rare \u03b2-globin gene mutations in a patient with \u03b2-thalassemia intermedia from Azerbaijan. Hemoglobin. 2013;37:291\u20136.","journal-title":"Hemoglobin"},{"issue":"24","key":"2411_CR12","doi-asserted-by":"publisher","first-page":"2797","DOI":"10.1093\/hmg\/10.24.2797","volume":"10","author":"V Viprakasit","year":"2001","unstructured":"Viprakasit V, Gibbons RJ, Broughton BC, Tolmie JL, Brown D, Lunt P, et al. Mutations in the general transcription factor TFIIH result in beta-thalassaemia in individuals with trichothiodystrophy. Hum Mol Genet. 2001;10(24):2797\u2013802.","journal-title":"Hum Mol Genet"},{"issue":"6","key":"2411_CR13","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1182\/blood-2002-02-0387","volume":"100","author":"C Yu","year":"2002","unstructured":"Yu C, Niakan KK, Matsushita M, Stamatoyannopoulos G, Orkin SH, Raskind WH. X-linked thrombocytopenia with thalassemia from a mutation in the amino finger of GATA-1 affecting DNA binding rather than FOG-1 interaction. Blood. 2002;100(6):2040\u20135.","journal-title":"Blood"},{"issue":"4","key":"2411_CR14","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1159\/000203622","volume":"98","author":"THJ Huisman","year":"1997","unstructured":"Huisman THJ. Levels of HbA2 in heterozygotes and homozygotes for beta-thalassemia mutations: influence of mutations in the CACCC and ATAAA motifs of the beta-globin gene promoter. Acta Haematol. 1997;98(4):187\u201394.","journal-title":"Acta Haematol"},{"issue":"7577","key":"2411_CR15","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/nature15521","volume":"527","author":"MC Canver","year":"2015","unstructured":"Canver MC, Smith EC, Sher F, Pinello L, Sanjana NE, Shalem O, et al. BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis. Nature. 2015;527(7577):192\u20137.","journal-title":"Nature"},{"issue":"5","key":"2411_CR16","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1182\/blood-2014-03-561779","volume":"124","author":"D Liu","year":"2014","unstructured":"Liu D, Zhang X, Yu L, Cai R, Ma X, Zheng C, et al. KLF1 mutations are relatively more common in a thalassemia endemic region and ameliorate the severity of beta-thalassemia. Blood. 2014;124(5):803\u201311.","journal-title":"Blood"},{"key":"2411_CR17","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/ejhg.2014.131","volume":"23","author":"J Traeger-Synodinos","year":"2015","unstructured":"Traeger-Synodinos J, Harteveld CL, Old JM, et al. EMQN best practice guidelines for molecular and haematology methods for carrier identification and prenatal diagnosis of the haemoglobinopathies. Eur J Hum Genet. 2015;23:426\u201337.","journal-title":"Eur J Hum Genet"},{"issue":"6","key":"2411_CR18","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1007\/s00586-010-1357-2","volume":"19","author":"R Haidar","year":"2010","unstructured":"Haidar R, Mhaidli H, Taher AT. Paraspinal extramedullary hematopoiesis in patients with thalassemia intermedia. Eur Spine J. 2010;19(6):871\u20138.","journal-title":"Eur Spine J"},{"issue":"Suppl 1","key":"2411_CR19","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.1016\/S0268-960X(12)70006-1","volume":"26","author":"KM Musallam","year":"2012","unstructured":"Musallam KM, Cappellini MD, Wood JC, Taher AT. Iron overload in non-transfusion-dependent thalassemia: a clinical perspective. Blood Rev. 2012;26(Suppl 1):S16\u20139.","journal-title":"Blood Rev"},{"issue":"5","key":"2411_CR20","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1002\/ajh.23405","volume":"88","author":"AT Taher","year":"2013","unstructured":"Taher AT, Viprakasit V, Musallam KM, Cappellini MD. Treating iron overload in patients with non-transfusion-dependent thalassemia. Am J Hematol. 2013;88(5):409\u201315.","journal-title":"Am J Hematol"},{"issue":"2","key":"2411_CR21","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1111\/bjh.14373","volume":"176","author":"JB Porter","year":"2017","unstructured":"Porter JB, Cappellini MD, Kattamis A, Viprakasit V, Musallam KM, Zhu Z, et al. Iron overload across the spectrum of non-transfusion-dependent thalassaemias: role of erythropoiesis, splenectomy and transfusions. Br J Haematol. 2017;176(2):288\u201399.","journal-title":"Br J Haematol"},{"issue":"Suppl1","key":"2411_CR22","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1016\/S0268-960X(12)70005-X","volume":"26","author":"S Rivella","year":"2012","unstructured":"Rivella S. The role of ineffective erythropoiesis in non-transfusion-dependent thalassemia. Blood Rev. 2012;26(Suppl1):S12\u20135.","journal-title":"Blood Rev"},{"issue":"7","key":"2411_CR23","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1172\/JCI32701","volume":"117","author":"I Domenico De","year":"2007","unstructured":"De Domenico I, Ward DM, Kaplan J. Hepcidin regulation: ironing out the details. J Clin Investig. 2007;117(7):1755\u20138.","journal-title":"J Clin Investig"},{"issue":"7","key":"2411_CR24","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1172\/JCI31370","volume":"117","author":"C Peyssonnaux","year":"2007","unstructured":"Peyssonnaux C, Zinkernagel AS, Schuepbach RA, Rankin E, Vaulont S, Haase VH, et al. Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs). J Clin Investig. 2007;117(7):1926\u201332.","journal-title":"J Clin Investig"},{"issue":"9","key":"2411_CR25","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1038\/nm1629","volume":"13","author":"T Tanno","year":"2007","unstructured":"Tanno T, Bhanu NV, Oneal PA, Goh SH, Staker P, Lee YT, et al. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med. 2007;13(9):1096\u2013101.","journal-title":"Nat Med"},{"issue":"7","key":"2411_CR26","doi-asserted-by":"publisher","first-page":"1000224","DOI":"10.4172\/2155-9864.1000224","volume":"5","author":"CD Asadov","year":"2014","unstructured":"Asadov CD. Immunologic abnormalities in \u03b2-thalassemia. J Blood Disord Transf. 2014;5(7):1000224.","journal-title":"J Blood Disord Transf"},{"issue":"4","key":"2411_CR27","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1046\/j.1365-2141.2001.03200.x","volume":"115","author":"R Galanello","year":"2001","unstructured":"Galanello R, Piras S, Barella S, Leoni GB, Cipollina MD, Perseu L, et al. Cholelithiasis and Gilbert\u2019s syndrome in homozygous beta-thalassemia. Br J Haematol. 2001;115(4):926\u20138.","journal-title":"Br J Haematol"},{"issue":"10","key":"2411_CR28","first-page":"1106","volume":"88","author":"C Borgna-Pignatti","year":"2003","unstructured":"Borgna-Pignatti C, Rigon F, Merlo L, Chakrok R, Micciolo R, Perseu L, et al. Thalassemia minor, the Gilbert mutation, and the risk of gallstones. Haematologica. 2003;88(10):1106\u20139.","journal-title":"Haematologica"},{"issue":"1","key":"2411_CR29","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S1665-2681(19)31397-3","volume":"12","author":"JE Maakaron","year":"2013","unstructured":"Maakaron JE, Cappellini MD, Graziadei G, Ayache JB, Taher AT. Hepatocellular carcinoma in hepatitis-negative patients with thalassemia intermedia: a closer look at the role of siderosis. Ann Hepatol. 2013;12(1):142\u20136.","journal-title":"Ann Hepatol"},{"issue":"5","key":"2411_CR30","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1002\/cncr.30462","volume":"123","author":"HM Moukhadder","year":"2017","unstructured":"Moukhadder HM, Halawi R, Cappellini MD, Taher AT. Hepatocellular carcinoma as an emerging morbidity in the thalassemia syndromes: a comprehensive review. Cancer. 2017;123(5):751\u20138.","journal-title":"Cancer"},{"issue":"5","key":"2411_CR31","doi-asserted-by":"publisher","first-page":"821","DOI":"10.5301\/jn.5000253","volume":"26","author":"NS Mallat","year":"2013","unstructured":"Mallat NS, Mallat SG, Musallam KM, Taher AT. Potential mechanisms for renal damage in beta-thalassemia. J Nephrol. 2013;26(5):821\u20138.","journal-title":"J Nephrol"},{"issue":"6","key":"2411_CR32","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.blre.2010.08.004","volume":"24","author":"C Ponticelli","year":"2010","unstructured":"Ponticelli C, Musallam KM, Cianciulli P, Cappellini MD. Renal complications in transfusion-dependent beta thalassaemia. Blood Rev. 2010;24(6):239\u201344.","journal-title":"Blood Rev"},{"issue":"2","key":"2411_CR33","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1097\/00006534-198202000-00023","volume":"69","author":"Z Gimmon","year":"1982","unstructured":"Gimmon Z, Wexler MR, Rachmilewitz EA. Juvenile leg ulceration in beta-thalassemia major and intermedia. Plast Reconstr Surg. 1982;69(2):320\u20135.","journal-title":"Plast Reconstr Surg"},{"issue":"5","key":"2411_CR34","first-page":"316","volume":"13","author":"C Levin","year":"2011","unstructured":"Levin C, Koren A. Healing of refractory leg ulcer in a patient with thalassemia intermedia and hypercoagulability after 14\u00a0years of unresponsive therapy. Isr Med Assoc J. 2011;13(5):316\u20138.","journal-title":"Isr Med Assoc J"},{"issue":"1","key":"2411_CR35","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1159\/000204799","volume":"86","author":"AK Al Momen","year":"1991","unstructured":"Al Momen AK. Recombinant human erythropoietin induced rapid healing of a chronic leg ulcer in a patient with sickle cell disease. Acta Haematol. 1991;86(1):46\u20138.","journal-title":"Acta Haematol"},{"issue":"2","key":"2411_CR36","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1111\/ijd.13443","volume":"56","author":"H Afradi","year":"2017","unstructured":"Afradi H, Saghaei Y, Kachoei ZA, Babaei V, Teimourian S. Treatment of 100 chronic thalassemic leg wounds by plasma-rich platelets. Int J Dermatol. 2017;56(2):171\u20135.","journal-title":"Int J Dermatol"},{"issue":"4","key":"2411_CR37","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1160\/TH06-05-0267","volume":"96","author":"A Taher","year":"2006","unstructured":"Taher A, Isma\u2019eel H, Mehio G, Bignamini D, Kattamis A, Rachmilewitz EA, et al. Prevalence of thromboembolic events among 8860 patients with thalassaemia major and intermedia in the Mediterranean area and Iran. Thromb Haemost. 2006;96(4):488\u201391.","journal-title":"Thromb Haemost"},{"issue":"Suppl 1","key":"2411_CR38","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1016\/S0268-960X(12)70007-3","volume":"26","author":"MD Cappellini","year":"2012","unstructured":"Cappellini MD, Musallam KM, Poggiali E, Taher AT. Hypercoagulability in non-transfusion-dependent thalassemia. Blood Rev. 2012;26(Suppl 1):S20\u20133.","journal-title":"Blood Rev"},{"issue":"1","key":"2411_CR39","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1002\/ajh.2830440114","volume":"44","author":"V Borenstain-Ben Yashar","year":"1993","unstructured":"Borenstain-Ben Yashar V, Barenholz Y, Hy-Am E, Rachmilewitz EA, Eldor A. Phosphatidylserine in the outer leaflet of red blood cells from beta-thalassemia patients may explain the chronic hypercoagulable state and thrombotic episodes. Am J Hematol. 1993;44(1):63\u20135.","journal-title":"Am J Hematol"},{"issue":"3","key":"2411_CR40","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1055\/s-0038-1650577","volume":"76","author":"D Helley","year":"1996","unstructured":"Helley D, Eldor A, Girot R, Ducrocq R, Guillin MC, Bezeaud A. Increased procoagulant activity of red blood cells from patients with homozygous sickle cell disease and beta-thalassemia. Thromb Haemost. 1996;76(3):322\u20137.","journal-title":"Thromb Haemost"},{"issue":"6 Pt 2","key":"2411_CR41","first-page":"H1951","volume":"270","author":"S Chen","year":"1996","unstructured":"Chen S, Eldor A, Barshtein G, Zhang S, Golfarb A, Rachmilewitz E, et al. Enhanced aggregability of red blood cells of beta-thalassemia major patients. Am J Physiol. 1996;270(6 Pt 2):H1951\u20136.","journal-title":"Am J Physiol"},{"issue":"1","key":"2411_CR42","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1046\/j.1365-2141.1997.1502965.x","volume":"98","author":"A Ruf","year":"1997","unstructured":"Ruf A, Pick M, Deutsch V, Patscheke H, Goldfarb A, Rachmilewitz EA, et al. In-vivo platelet activation correlates with red cell anionic phospholipid exposure in patients with beta-thalassaemia major. Br J Haematol. 1997;98(1):51\u20136.","journal-title":"Br J Haematol"},{"issue":"4","key":"2411_CR43","first-page":"556","volume":"12","author":"P Winichagoon","year":"1981","unstructured":"Winichagoon P, Fucharoen S, Wasi P. Increased circulating platelet aggregates in thalassaemia. Southeast Asian J Trop Med Public Health. 1981;12(4):556\u201360.","journal-title":"Southeast Asian J Trop Med Public Health"},{"issue":"1","key":"2411_CR44","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1111\/j.1365-2141.1993.tb03033.x","volume":"84","author":"D Principle Del","year":"1993","unstructured":"Del Principle D, Menichelli A, Di Giulio S, De Matteis W, Cianciulli P, Papa G. PADGEM\/GMP-140 expression on platelet membranes from homozygous beta thalassaemic patients. Br J Haematol. 1993;84(1):111\u20137.","journal-title":"Br J Haematol"},{"issue":"3","key":"2411_CR45","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1111\/j.1365-2141.2006.06449.x","volume":"136","author":"K Pattanapanyasat","year":"2007","unstructured":"Pattanapanyasat K, Gonwong S, Chaichompoo P, Noulsri E, Lerdwana S, Sukapirom K, et al. Activated platelet-derived microparticles in thalassaemia. Br J Haematol. 2007;136(3):462\u201371.","journal-title":"Br J Haematol"},{"issue":"10","key":"2411_CR46","first-page":"1112","volume":"86","author":"A Iolascon","year":"2001","unstructured":"Iolascon A, Giordano P, Storelli S, Li HH, Coppola B, Piga A, et al. Thrombophilia in thalassemia major patients: analysis of genetic predisposing factors. Haematologica. 2001;86(10):1112\u20133.","journal-title":"Haematologica"},{"issue":"4","key":"2411_CR47","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1080\/10245330600954130","volume":"11","author":"S Sharma","year":"2006","unstructured":"Sharma S, Raina V, Chandra J, Narayan S, Sharma S. Lupus anticoagulant and anticardiolipin antibodies in polytransfused beta thalassemia major. Hematology. 2006;11(4):287\u201390.","journal-title":"Hematology"},{"issue":"1","key":"2411_CR48","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1182\/blood.V99.1.36","volume":"99","author":"A Eldor","year":"2002","unstructured":"Eldor A, Rachmilewitz EA. The hypercoagulable state in thalassemia. Blood. 2002;99(1):36\u201343.","journal-title":"Blood"},{"issue":"2","key":"2411_CR49","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1046\/j.1365-2141.2000.02376.x","volume":"111","author":"MD Cappellini","year":"2000","unstructured":"Cappellini MD, Robbiolo L, Bottasso BM, Coppola R, Fiorelli G, Manucci AP. Venous thromboembolism and hypercoagulability in splenectomized patients with thalassaemia intermedia. Br J Haematol. 2000;111(2):467\u201373.","journal-title":"Br J Haematol"},{"issue":"11","key":"2411_CR50","doi-asserted-by":"publisher","first-page":"3411","DOI":"10.1182\/blood.V97.11.3411","volume":"97","author":"A Aessopos","year":"2001","unstructured":"Aessopos A, Farmakis D, Karagiorga M, Voskaridou E, Loutradi A, Hatziliami A, et al. Cardiac involvement in thalassemia intermedia: a multicenter study. Blood. 2001;97(11):3411\u20136.","journal-title":"Blood"},{"issue":"3","key":"2411_CR51","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1161\/CIRCULATIONAHA.113.002124","volume":"129","author":"G Derchi","year":"2014","unstructured":"Derchi G, Galanello R, Bina P, Cappellini MD, Piga A, Lai ME, et al. Prevalence and risk factors for pulmonary arterial hypertension in a large group of \u03b2-thalassemia patients using right heart catheterization: a Webthal study. Circulation. 2014;129(3):338\u201345.","journal-title":"Circulation"},{"issue":"2","key":"2411_CR52","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/BF02983382","volume":"78","author":"V Atichartakarn","year":"2003","unstructured":"Atichartakarn V, Likittanasombat K, Chuncharunee S, Chandanamattha P, Worapongpaiboon S, Angchaisuksi P, et al. Pulmonary arterial hypertension in previously splenectomized patients with beta-thalassemic disorders. Int J Hematol. 2003;78(2):139\u201345.","journal-title":"Int J Hematol"},{"issue":"7","key":"2411_CR53","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1182\/blood-2003-09-3094","volume":"103","author":"V Atichartakarn","year":"2004","unstructured":"Atichartakarn V, Chuncharunee S, Chandanamattha P, Likittanasombat K, Aryurachai K. Pulmonary arterial hypertension in previously splenectomized patients with beta-thalassemic disorders. Blood. 2004;103(7):2844\u20136.","journal-title":"Blood"},{"issue":"4","key":"2411_CR54","first-page":"260","volume":"63","author":"AU Kurtoglu","year":"2012","unstructured":"Kurtoglu AU, Kurtoglu E, Temizkan AK. Effect of iron overload on endocrinopathies in patients with beta-thalassemia major and intermedia. Endokrynol Polska. 2012;63(4):260\u20133.","journal-title":"Endokrynol Polska"},{"issue":"2","key":"2411_CR55","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1097\/00006254-199402000-00025","volume":"49","author":"C Savona-Ventura","year":"1994","unstructured":"Savona-Ventura C, Bonello F. Beta-thalassemia syndromes and pregnancy. Obstetr Gynecol Surv. 1994;49(2):129\u201337.","journal-title":"Obstetr Gynecol Surv"},{"key":"2411_CR56","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.2469","author":"JE Roumi","year":"2017","unstructured":"Roumi JE, Moukhadder HM, Graziadei G, Pennisi M, Cappellini MD, Taher AT. Pregnancy in \u03b2-thalassemia intermedia at two tertiary care centers in Lebanon and Italy: a follow-up report on fetal and maternal outcomes. Am J Hematol. 2017. https:\/\/doi.org\/10.1002\/ajh.2469 (Epub ahead of print).","journal-title":"Am J Hematol."},{"issue":"7","key":"2411_CR57","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1002\/ajh.20654","volume":"81","author":"AH Nassar","year":"2006","unstructured":"Nassar AH, Usta IM, Rechda JB, Koussa S, Inati A, Taher AT. Pregnancy in patients with beta-thalassemia intermedia: outcome of mothers and newborns. Am J Hematol. 2006;81(7):499\u2013502.","journal-title":"Am J Hematol"},{"issue":"3","key":"2411_CR58","doi-asserted-by":"publisher","first-page":"376","DOI":"10.3324\/haematol.2009.012393","volume":"95","author":"R Origa","year":"2010","unstructured":"Origa R, Piga A, Quarta G, Forni GL, Longo F, Melpignano A, et al. Pregnancy and beta-thalassemia: an Italian multicenter experience. Haematologica. 2010;95(3):376\u201381.","journal-title":"Haematologica"},{"issue":"8","key":"2411_CR59","first-page":"441","volume":"8","author":"G Petrakos","year":"2016","unstructured":"Petrakos G, Andriopoulos P, Tsironi M. Pregnancy in women with thalassemia: challenges and solutions. Int J Womens Health. 2016;8(8):441\u201351.","journal-title":"Int J Womens Health"},{"issue":"2","key":"2411_CR60","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1046\/j.1365-2141.2000.02382.x","volume":"111","author":"S Perrotta","year":"2000","unstructured":"Perrotta S, Cappellini MD, Bertoldo F, Servedio V, Iolascon G, D\u2019Agruma L, et al. Osteoporosis in beta-thalassaemia major patients: analysis of the genetic background. Br J Haematol. 2000;111(2):461\u20136.","journal-title":"Br J Haematol"},{"issue":"3","key":"2411_CR61","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.bone.2010.10.173","volume":"48","author":"R Haidar","year":"2011","unstructured":"Haidar R, Musallam KM, Taher AT. Bone disease and skeletal complications in patients with \u03b2-thalassemia major. Bone. 2011;48(3):425\u201332.","journal-title":"Bone"},{"issue":"1","key":"2411_CR62","first-page":"399","volume":"4","author":"Y Sien","year":"2014","unstructured":"Sien Y, Yusoff A, Shahar S, Rajikan R. Bone health status among thalassemia children. Int J Public Health Res. 2014;4(1):399\u2013404.","journal-title":"Int J Public Health Res"},{"issue":"Suppl 3","key":"2411_CR63","first-page":"795","volume":"11","author":"B Wonke","year":"1998","unstructured":"Wonke B, Jensen C, Hanslip JJ, Prescott E, Lalloz M, Layton M, et al. Genetic and acquired predisposing factors and treatment of osteoporosis in thalassaemia major. J Pediatr Endocrinol Metab. 1998;11(Suppl 3):795\u2013801.","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"4","key":"2411_CR64","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.bone.2005.10.001","volume":"38","author":"MG Vogiatzi","year":"2006","unstructured":"Vogiatzi MG, Macklin EA, Fung EB, Vichinsky E, Olivieri N, Kwiatkowski J, et al. Prevalence of fractures among the thalassemia syndromes in North America. Bone. 2006;38(4):571\u20135.","journal-title":"Bone"},{"issue":"1","key":"2411_CR65","first-page":"29","volume":"44","author":"M Karimi","year":"2007","unstructured":"Karimi M, Ghiam AF, Hashemi A, Alinejad S, Soweid M, Kashef S. Bone mineral density in beta-thalassemia major and intermedia. Indian Pediatr. 2007;44(1):29\u201332.","journal-title":"Indian Pediatr"},{"issue":"6","key":"2411_CR66","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/j.bone.2005.11.018","volume":"38","author":"N Napoli","year":"2006","unstructured":"Napoli N, Carmina E, Bucchieri S, Sferrazza C, Rini GB, Di Fede G. Low serum levels of 25-hydroxy vitamin D in adults affected by thalassemia major or intermedia. Bone. 2006;38(6):888\u201392.","journal-title":"Bone"},{"key":"2411_CR67","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1196\/annals.1345.063","volume":"1054","author":"MG Vogiatzi","year":"2005","unstructured":"Vogiatzi MG, Autio KA, Mait JE, Schneider R, Lesser M, Giardina PJ. Low bone mineral density in adolescents with beta-thalassemia. Ann N Y Acad Sci. 2005;1054:462\u20136.","journal-title":"Ann N Y Acad Sci"},{"issue":"2","key":"2411_CR68","first-page":"902","volume":"111","author":"RD Pollak","year":"2000","unstructured":"Pollak RD, Rachmilewitz E, Blumenfeld A, Idelson M, Goldfarb AW. Bone mineral metabolism in adults with beta-thalassaemia major and intermedia. Br J Haematol. 2000;111(2):902\u20137.","journal-title":"Br J Haematol"},{"issue":"5","key":"2411_CR69","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1359\/jbmr.040113","volume":"19","author":"N Morabito","year":"2004","unstructured":"Morabito N, Gaudio A, Lasco A, Atteritano M, Pizzoleo MA, Cincotta M, et al. Osteoprotegerin and RANKL in the pathogenesis of thalassemia-induced osteoporosis: new pieces of the puzzle. J Bone Miner Res. 2004;19(5):722\u20137.","journal-title":"J Bone Miner Res"},{"issue":"3","key":"2411_CR70","first-page":"143","volume":"6","author":"M Hashemieh","year":"2014","unstructured":"Hashemieh M, Azarkeivan A, Radfar M, Saneifard H, Hosseini-Zijoud SM, Noghabaei G, et al. Prevalence of osteoporosis among thalassemia patients from Zafar adult thalassemia clinic. Iran J Blood Cancer. 2014;6(3):143\u20138.","journal-title":"Iran J Blood Cancer"},{"issue":"1","key":"2411_CR71","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1046\/j.1365-2141.2001.02549.x","volume":"112","author":"E Voskaridou","year":"2001","unstructured":"Voskaridou E, Kyrtsonis MC, Terpos E, Skordili M, Theodoropoulos I, Bergele A, et al. Bone resorption is increased in young adults with thalassaemia major. Br J Haematol. 2001;112(1):36\u201341.","journal-title":"Br J Haematol"},{"key":"2411_CR72","doi-asserted-by":"publisher","first-page":"813098","DOI":"10.1155\/2015\/813098","volume":"2015","author":"A Inati","year":"2015","unstructured":"Inati A, Noureldine MA, Mansour A, Abbas HA. Endocrine and bone complications in \u03b2-thalassemia intermedia: current understanding and treatment. Biomed Res Int. 2015;2015:813098.","journal-title":"Biomed Res Int"},{"issue":"3","key":"2411_CR73","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1111\/j.1365-2141.2007.06654.x","volume":"138","author":"C Borgna-Pignatti","year":"2007","unstructured":"Borgna-Pignatti C. Modern treatment of thalassaemia intermedia. Br J Haematol. 2007;138(3):291\u2013304.","journal-title":"Br J Haematol"},{"issue":"1","key":"2411_CR74","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/nyas.13041","volume":"1368","author":"A Giusti","year":"2016","unstructured":"Giusti A, Pinto V, Forni GL, Pilotto A. Management of beta-thalassemia-associated osteoporosis. Ann N Y Acad Sci. 2016;1368(1):73\u201381.","journal-title":"Ann N Y Acad Sci"},{"issue":"2","key":"2411_CR75","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1111\/j.1365-2141.2012.09152.x","volume":"158","author":"GL Forni","year":"2012","unstructured":"Forni GL, Perrotta S, Giusti A, Quarta G, Pitrolo L, Cappellini MD, et al. Neridronate improves bone mineral density and reduces back pain in \ud835\udefd-thalassaemia patients with osteoporosis: results from a phase 2, randomized, parallel-arm, open-label study. Br J Haematol. 2012;158(2):274\u201382.","journal-title":"Br J Haematol"},{"issue":"1","key":"2411_CR76","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/j.1600-0609.2011.01623.x","volume":"87","author":"KM Musallam","year":"2011","unstructured":"Musallam KM, Khoury B, Abi-Habib R, Bazzi L, Succar J, Halawi R, et al. Health-related quality of life in adults with transfusion-independent thalassaemia intermedia compared to regularly transfused thalassaemia major: new insights. Eur J Haematol. 2011;87(1):73\u20139.","journal-title":"Eur J Haematol"},{"issue":"1","key":"2411_CR77","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1185\/03007995.2015.1110128","volume":"32","author":"E Vichinsky","year":"2016","unstructured":"Vichinsky E. Non-transfusion-dependent thalassemia and thalassemia intermedia: epidemiology, complications, and management. Curr Med Res Opin. 2016;32(1):191\u2013204.","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"2411_CR78","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/j.1538-7836.2009.03651.x","volume":"8","author":"AT Taher","year":"2010","unstructured":"Taher AT, Musallam KM, Nasreddine W, Hourani R, Inati A, Beydoun A. Asymptomatic brain magnetic resonance imaging abnormalities in splenectomized adults with thalassemia intermedia. J Thromb Haemost. 2010;8(1):54\u20139.","journal-title":"J Thromb Haemost"},{"issue":"14","key":"2411_CR79","doi-asserted-by":"publisher","first-page":"2861","DOI":"10.1182\/blood-2009-04-210112","volume":"114","author":"EC Shelley","year":"2009","unstructured":"Shelley EC, Buchanan GR. Vascular complications after splenectomy for hematologic disorders. Blood. 2009;114(14):2861\u20138.","journal-title":"Blood"},{"issue":"5","key":"2411_CR80","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.thromres.2012.07.013","volume":"130","author":"KM Musallam","year":"2012","unstructured":"Musallam KM, Taher AT, Karimi M, Rachmilewitz EA. Cerebral infarction in \u03b2-thalassemia intermedia: breaking the silence. Thromb Res. 2012;130(5):695\u2013702.","journal-title":"Thromb Res"},{"key":"2411_CR81","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1046\/j.1365-2141.2001.02482.x","volume":"112","author":"D Tavazzi","year":"2001","unstructured":"Tavazzi D, Duca L, Graziadei G, et al. Membrane-bound iron contributes to oxidative damage of \u03b2-thalassaemia intermedia erythrocytes. Br J Haematol. 2001;112:48\u201350.","journal-title":"Br J Haematol"},{"issue":"5","key":"2411_CR82","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1111\/j.1365-2141.2010.08486.x","volume":"152","author":"AT Taher","year":"2011","unstructured":"Taher AT, Musallam KM, Cappellini MD, Weatherall DJ. Optimal management of beta-thalassaemia intermedia. Br J Haematol. 2011;152(5):512\u201323.","journal-title":"Br J Haematol"},{"key":"2411_CR83","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010517.pub2","author":"M Easow Mathew","year":"2016","unstructured":"Easow Mathew M, Sharma A, Aravindakshan R. Splenectomy for people with thalassaemia major or intermedia. Cochrane Database Syst Rev. 2016. https:\/\/doi.org\/10.1002\/14651858.CD010517.pub2 .","journal-title":"Cochrane Database Syst Rev"},{"key":"2411_CR84","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1111\/j.1537-2995.2007.01192.x","volume":"47","author":"A Aessopos","year":"2007","unstructured":"Aessopos A, Kati M, Meletis J. Thalassemia intermedia today: should patients regularly receive transfusions? Transfusion. 2007;47:792\u2013800.","journal-title":"Transfusion"},{"issue":"1","key":"2411_CR85","first-page":"50","volume":"58","author":"T Spanos","year":"1990","unstructured":"Spanos T, Karageorga M, Ladis V, Peristeri J, Hatziliami A, Kattamis C. Red cell alloantibodies in patients with thalassemia. Vox Sang. 1990;58(1):50\u20135.","journal-title":"Vox Sang"},{"issue":"4","key":"2411_CR86","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1111\/ijlh.12362","volume":"37","author":"I Seferi","year":"2015","unstructured":"Seferi I, Xhetani M, Face M, Burazeri G, Nastas E, Vyshka G. Frequency and specificity of red cell antibodies in thalassemia patients in Albania. Int J Lab Hematol. 2015;37(4):569\u201374.","journal-title":"Int J Lab Hematol"},{"issue":"1","key":"2411_CR87","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/vox.12201","volume":"108","author":"AT Taher","year":"2015","unstructured":"Taher AT, Radwan A, Viprakasit V. When to consider transfusion therapy for patients with non-transfusion-dependent thalassaemia. Vox Sang. 2015;108(1):1\u201310.","journal-title":"Vox Sang"},{"issue":"2\u20133","key":"2411_CR88","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.bcmd.2013.08.006","volume":"52","author":"AT Taher","year":"2014","unstructured":"Taher AT, Musallam KM, Viprakasit V, Porter JB, Cappellini MD. Iron chelation therapy for non-transfusion-dependent thalassemia (NTDT): a status quo. Blood Cells Mol Dis. 2014;52(2\u20133):88\u201390.","journal-title":"Blood Cells Mol Dis"},{"issue":"5","key":"2411_CR89","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1111\/j.1365-2141.2009.07848.x","volume":"147","author":"A Taher","year":"2009","unstructured":"Taher A, Hershko C, Cappellini MD. Iron overload in thalassaemia intermedia: reassessment of iron chelation strategies. Br J Haematol. 2009;147(5):634\u201340.","journal-title":"Br J Haematol"},{"issue":"11","key":"2411_CR90","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.3324\/haematol.2011.047852","volume":"96","author":"KM Musallam","year":"2011","unstructured":"Musallam KM, Cappellini MD, Wood JC, Motta I, Graziadei G, Tamim H, et al. Elevated liver iron concentration is a marker of increased morbidity in patients with beta thalassemia intermedia. Haematologica. 2011;96(11):1605\u201312.","journal-title":"Haematologica"},{"issue":"6","key":"2411_CR91","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s00277-009-0879-3","volume":"89","author":"A Roghi","year":"2010","unstructured":"Roghi A, Cappellini MD, Wood JC, Musallam KM, Patrizia P, Fasulo MR, et al. Absence of cardiac siderosis despite hepatic iron overload in Italian patients with thalassemia intermedia: an MRI T2* study. Ann Hematol. 2010;89(6):585\u20139.","journal-title":"Ann Hematol"},{"issue":"6","key":"2411_CR92","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1080\/21678707.2016.1182018","volume":"4","author":"R Halawi","year":"2016","unstructured":"Halawi R, Motta I, Taher A, Cappellini MD. Deferasirox: an orphan drug for chronic iron overload in non-transfusion dependent thalassemia syndromes. Expert Opin Orphan Drugs. 2016;4(6):677\u201386.","journal-title":"Expert Opin Orphan Drugs"},{"key":"2411_CR93","doi-asserted-by":"publisher","first-page":"465","DOI":"10.2147\/DDDT.S79458","volume":"10","author":"CN Kontoghiorghe","year":"2016","unstructured":"Kontoghiorghe CN, Kontoghiorghes GJ. Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes. Drug Des Dev Ther. 2016;10:465\u201381.","journal-title":"Drug Des Dev Ther"},{"issue":"2","key":"2411_CR94","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1586\/17474086.2016.1126176","volume":"9","author":"AN Saliba","year":"2016","unstructured":"Saliba AN, El Rassi F, Taher AT. Clinical monitoring and management of complications related to chelation therapy in patients with \u03b2-thalassemia. Expert Rev Hematol. 2016;9(2):151\u201368.","journal-title":"Expert Rev Hematol"},{"issue":"12","key":"2411_CR95","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1182\/blood-2012-10-408021","volume":"121","author":"KM Musallam","year":"2013","unstructured":"Musallam KM, Taher AT, Cappellini MD, Sankaran VG. Clinical experience with fetal hemoglobin induction therapy in patients with \u03b2-thalassemia. Blood. 2013;121(12):2199\u2013212.","journal-title":"Blood"},{"key":"2411_CR96","first-page":"CD011579","volume":"10","author":"WC Foong","year":"2016","unstructured":"Foong WC, Ho JJ, Loh CK, Viprakasit V. Hydroxyurea for reducing blood transfusion in non-transfusion dependent beta thalassaemias. Cochrane Database Syst Rev. 2016;10:CD011579.","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"2411_CR97","doi-asserted-by":"publisher","first-page":"560","DOI":"10.3109\/08880010903271671","volume":"26","author":"MA Ehsani","year":"2009","unstructured":"Ehsani MA, Hedayati-Asl AA, Bagheri A, Zeinali S, Rashidi A. Hydroxyurea-induced hematological response in transfusion-independent beta-thalassemia intermedia: case series and review of literature. Pediatr Hematol Oncol. 2009;26(8):560\u20135.","journal-title":"Pediatr Hematol Oncol"},{"issue":"6","key":"2411_CR98","first-page":"86","volume":"255","author":"C Asadov","year":"2016","unstructured":"Asadov C, Alimirzoeva Z, Hasanova M, Mammadova T, Shirinova A. Clinical application of recombinant erythropoietin in beta-thalassemia intermedia. Georgian Med News. 2016;255(6):86\u201392.","journal-title":"Georgian Med News"},{"issue":"Supl1","key":"2411_CR99","first-page":"526","volume":"38","author":"Z Alimirzoeva","year":"2014","unstructured":"Alimirzoeva Z, Hasanova M, Asadov C. Modern principles of management of thalassemia intermedia. Leuk Res. 2014;38(Supl1):526\u20137.","journal-title":"Leuk Res"},{"key":"2411_CR100","first-page":"16","volume":"1","author":"C Asadov","year":"2012","unstructured":"Asadov C, Hasanova M, Alimirzoeva Z, Mammadova T. Serum erythropoietin in intermediate \u03b2-thalassemias. Klin Lab Diagn. 2012;1:16\u20138.","journal-title":"Klin Lab Diagn"},{"key":"2411_CR101","first-page":"46","volume":"226","author":"M Hasanova","year":"2014","unstructured":"Hasanova M, Asadov C, Alimirzoeva Z, Mammadova T, Shirinova A. Efficiency of recombinant erythropoietin administration in hemoglobinopathy H. Georgian Med News. 2014;226:46\u20139.","journal-title":"Georgian Med News"},{"issue":"6","key":"2411_CR102","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1111\/ejh.12182","volume":"91","author":"MS Elafy","year":"2013","unstructured":"Elafy MS, Adly AA, Ismail EA, Elhenawy YI, Elghamry IR. Therapeutic superiority and safety of combined hydroxyurea with recombinant human erythropoietin over hydroxyurea in young \u03b2-thalassemia intermedia patients. Eur J Haematol. 2013;91(6):522\u201333.","journal-title":"Eur J Haematol"},{"issue":"2","key":"2411_CR103","doi-asserted-by":"publisher","first-page":"214","DOI":"10.3324\/haematol.2015.141200","volume":"102","author":"A Srivastava","year":"2017","unstructured":"Srivastava A, Shaji RV. Cure for thalassemia major\u2014from allogeneic hematopoietic stem cell transplantation to gene therapy. Haematologica. 2017;102(2):214\u201323.","journal-title":"Haematologica"},{"issue":"21","key":"2411_CR104","doi-asserted-by":"publisher","first-page":"2536","DOI":"10.1182\/blood-2016-01-678128","volume":"127","author":"MC Canver","year":"2016","unstructured":"Canver MC, Orkin SH. Customizing the genome as therapy for the \u03b2-hemoglobinopathies. Blood. 2016;127(21):2536\u201345.","journal-title":"Blood"},{"issue":"4","key":"2411_CR105","doi-asserted-by":"publisher","first-page":"418","DOI":"10.3324\/haematol.2014.114827","volume":"100","author":"S Rivella","year":"2015","unstructured":"Rivella S. \u03b2-thalassemias: paradigmatic diseases for scientific discoveries and development of innovative therapies. Haematologica. 2015;100(4):418\u201330.","journal-title":"Haematologica"},{"issue":"3","key":"2411_CR106","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1182\/blood-2007-12-126938","volume":"112","author":"IV Libani","year":"2008","unstructured":"Libani IV, Guy EC, Melchiori L, Schiro R, Ramos P, Breda L, et al. Decreased differentiation of erythroid cells exacerbates ineffective erythropoiesis in beta-thalassemia. Blood. 2008;112(3):875\u201385.","journal-title":"Blood"},{"key":"2411_CR107","doi-asserted-by":"publisher","first-page":"938640","DOI":"10.1155\/2010\/938640","volume":"2010","author":"L Melchiori","year":"2010","unstructured":"Melchiori L, Gardenghi S, Rivella S. \u03b2-Thalassemia: HiJAKing ineffective erythropoiesis and iron overload. Adv Hematol. 2010;2010:938640.","journal-title":"Adv Hematol"},{"issue":"22","key":"2411_CR108","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1182\/blood.V114.22.2020.2020","volume":"114","author":"L Melchiori","year":"2009","unstructured":"Melchiori L, Gardenghi S, Guy EG, Rachmilewitz E, Giardina PJ, Grady RW, et al. Use of JAK2 inhibitors to limit ineffective erythropoiesis and iron absorption in mice affected by \u03b2-thalassemia and other disorders of red cell production. Blood. 2009;114(22):2020.","journal-title":"Blood"},{"issue":"22","key":"2411_CR109","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1182\/blood.V128.22.852.852","volume":"128","author":"Y Aydinok","year":"2016","unstructured":"Aydinok Y, Karakas Z, Cassinerio E, Siritanaratkul N, Kattamis A, Maggio A, et al. Efficacy and safety of ruxolitinib in regularly transfused patients with thalassemia: results from single-arm, multicenter, phase 2a truth study. Blood. 2016;128(22):852.","journal-title":"Blood"},{"issue":"12","key":"2411_CR110","doi-asserted-by":"publisher","first-page":"4466","DOI":"10.1172\/JCI41717","volume":"120","author":"S Gardenghi","year":"2010","unstructured":"Gardenghi S, Ramos P, Marongiu MF, Melchiori L, Breda L, Guy E, et al. Hepcidin as a therapeutic tool to limit iron overload and improve anemia in beta-thalassemic mice. J Clin Investig. 2010;120(12):4466\u201377.","journal-title":"J Clin Investig"},{"issue":"3","key":"2411_CR111","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1586\/ehm.11.22","volume":"4","author":"NL Parrow","year":"2011","unstructured":"Parrow NL, Gardenghi S, Rivella S. Prospects for a hepcidin mimic to treat beta-thalassemia and hemochromatosis. Expert Rev Hematol. 2011;4(3):233\u20135.","journal-title":"Expert Rev Hematol"},{"issue":"12","key":"2411_CR112","doi-asserted-by":"publisher","first-page":"4880","DOI":"10.1172\/JCI57693","volume":"121","author":"GC Preza","year":"2011","unstructured":"Preza GC, Ruchala P, Pinon R, Ramos E, Qiao B, Peralta MA, et al. Minihepcidins are rationally designed small peptides that mimic hepcidin activity in mice and may be useful for the treatment of iron overload. J Clin Investig. 2011;121(12):4880\u20138.","journal-title":"J Clin Investig"},{"issue":"5879","key":"2411_CR113","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1126\/science.1157121","volume":"320","author":"X Du","year":"2008","unstructured":"Du X, She E, Gelbart T, Truksa J, Lee P, Xia Y, et al. The serine protease TMPRSS6 is required to sense iron deficiency. Science. 2008;320(5879):1088\u201392.","journal-title":"Science"},{"issue":"18","key":"2411_CR114","doi-asserted-by":"publisher","first-page":"3817","DOI":"10.1182\/blood-2009-05-224808","volume":"115","author":"KE Finberg","year":"2010","unstructured":"Finberg KE, Whittlesey RL, Fleming MD, Andrews NC. Down-regulation of Bmp\/Smad signaling by Tmprss6 is required for maintenance of systemic iron homeostasis. Blood. 2010;115(18):3817\u201326.","journal-title":"Blood"},{"issue":"21","key":"2411_CR115","doi-asserted-by":"publisher","first-page":"5021","DOI":"10.1182\/blood-2012-01-401885","volume":"119","author":"A Nai","year":"2012","unstructured":"Nai A, Pagani A, Mandelli G, Lidonnici MR, Silvestri L, Ferrari G, et al. Deletion of TMPRSS6 attenuates the phenotype in a mouse model of beta-thalassemia. Blood. 2012;119(21):5021\u20139.","journal-title":"Blood"},{"issue":"4","key":"2411_CR116","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1172\/JCI66969","volume":"123","author":"S Guo","year":"2013","unstructured":"Guo S, Casu C, Gardenghi S, Booten S, Aghajan M, Peralta R, et al. Reducing TMPRSS6 ameliorates hemochromatosis and beta-thalassemia in mice. J Clin Investig. 2013;123(4):1531\u201341.","journal-title":"J Clin Investig"},{"issue":"7","key":"2411_CR117","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood-2012-09-453977","volume":"121","author":"PJ Schmidt","year":"2013","unstructured":"Schmidt PJ, Toudjarska I, Sendamarai A, Racie T, Milstein S, Bettencourt BR, et al. An RNAi therapeutic targeting Tmprss6 decreases iron overload in Hfe(\u2212\/\u2212) mice and ameliorates anemia and iron overload in murine beta-thalassemia intermedia. Blood. 2013;121(7):1200\u20138.","journal-title":"Blood"},{"issue":"2","key":"2411_CR118","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/nm.2073","volume":"16","author":"H Li","year":"2010","unstructured":"Li H, Rybicki AC, Suzuka SM, von Bonsdorff L, Breuer W, Hall CB, et al. Transferrin therapy ameliorates disease in beta-thalassemic mice. Nat Med. 2010;16(2):177\u201382.","journal-title":"Nat Med"},{"issue":"25","key":"2411_CR119","doi-asserted-by":"publisher","first-page":"3864","DOI":"10.1182\/blood-2013-06-511238","volume":"123","author":"RN Suragani","year":"2014","unstructured":"Suragani RN, Cawley SM, Li R, Wallner S, Alexander MJ, Mulivor AW, et al. Modified activin receptor IIB ligand trap mitigates ineffective erythropoiesis and disease complications in murine beta-thalassemia. Blood. 2014;123(25):3864\u201372.","journal-title":"Blood"},{"issue":"4","key":"2411_CR120","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/nm.3468","volume":"20","author":"M Dussiot","year":"2014","unstructured":"Dussiot M, Maciel TT, Fricot A, Chartier C, Negre O, Veiga J, et al. An activin receptor IIA ligand trap corrects ineffective erythropoiesis in beta-thalassemia. Nat Med. 2014;20(4):398\u2013407.","journal-title":"Nat Med"},{"issue":"4","key":"2411_CR121","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1038\/nm.3512","volume":"20","author":"RN Suragani","year":"2014","unstructured":"Suragani RN, Cadena SM, Cawley SM, Sako D, Mitchell D, Li R, et al. Transforming growth factor-beta superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis. Nat Med. 2014;20(4):408\u201314.","journal-title":"Nat Med"},{"issue":"21","key":"2411_CR122","doi-asserted-by":"crossref","first-page":"3448","DOI":"10.1182\/blood.V122.21.3448.3448","volume":"122","author":"MD Cappellini","year":"2013","unstructured":"Cappellini MD, Porter J, Origa R, Forni GR, Laadem A, Galacteros F, et al. A phase 2a, open-label, dose-finding study to determine the safety and tolerability of sotatercept (ACE-011) in adults with beta (\u03b2)-thalassemia: interim results. Blood. 2013;122(21):3448.","journal-title":"Blood"},{"issue":"21","key":"2411_CR123","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1182\/blood.V124.21.53.53","volume":"124","author":"AG Piga","year":"2014","unstructured":"Piga AG, Perrotta S, Melpignano A, Borgna-Pignatti C, Voskaridou E, Caruso V, et al. ACE-536 increases hemoglobin and decreases transfusion burden and serum ferritin in adults with beta-thalassemia: preliminary results from a phase 2 study. Blood. 2014;124(21):53.","journal-title":"Blood"},{"issue":"s1","key":"2411_CR124","first-page":"90","volume":"102","author":"AG Piga","year":"2017","unstructured":"Piga AG, Perrotta S, Melpignano A, Borgna-Pignatti C, Gamberini MR, Voskaridou E, et al. Luspatercept increases haemoglobin and improves quality of life in non-transfusion dependent adults with \u03b2-thalassemia. Haematologica. 2017;102(s1):90.","journal-title":"Haematologica"},{"issue":"50","key":"2411_CR125","doi-asserted-by":"publisher","first-page":"E4922","DOI":"10.1073\/pnas.1314197110","volume":"110","author":"ER Anderson","year":"2013","unstructured":"Anderson ER, Taylor M, Xue X, Ramakrishan SK, Martin A, Xie L, et al. Intestinal HIF2alpha promotes tissue-iron accumulation in disorders of iron overload with anemi. Proc Natl Acad Sci. 2013;110(50):E4922\u201330.","journal-title":"Proc Natl Acad Sci"},{"issue":"3","key":"2411_CR126","doi-asserted-by":"publisher","first-page":"e32345","DOI":"10.1371\/journal.pone.0032345","volume":"7","author":"L Breda","year":"2012","unstructured":"Breda L, Casu C, Gardenghi S, Bianchi N, Cartegni L, Narla M, et al. Therapeutic hemoglobin levels after gene transfer in beta-thalassemia mice and in hematopoietic cells of beta-thalassemia and sickle cells disease patients. PLoS One. 2012;7(3):e32345.","journal-title":"PLoS One"},{"issue":"7313","key":"2411_CR127","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/nature09328","volume":"467","author":"M Cavazzana-Calvo","year":"2010","unstructured":"Cavazzana-Calvo M, Payen E, Negre O, Wang G, Hehir K, Fusil F, et al. Transfusion independence and HMGA2 activation after gene therapy of human beta-thalassaemia. Nature. 2010;467(7313):318\u201322.","journal-title":"Nature"},{"issue":"10","key":"2411_CR128","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1182\/blood-2013-06-507178","volume":"123","author":"F Boulad","year":"2014","unstructured":"Boulad F, Wang X, Qu J, Taylor C, Ferro L, Karponi G, et al. Safe mobilization of CD34+ cells in adults with beta-thalassemia and validation of effective globin gene transfer for clinical investigation. Blood. 2014;123(10):1483\u20136.","journal-title":"Blood"},{"issue":"17","key":"2411_CR129","doi-asserted-by":"publisher","first-page":"2597","DOI":"10.1182\/blood-2014-12-615948","volume":"125","author":"MD Hoban","year":"2015","unstructured":"Hoban MD, Cost GJ, Mendel MC, Romero Z, Kaufman ML, Joglekar AV, et al. Correction of the sickle cell disease mutation in human hematopoietic stem\/progenitor cells. Blood. 2015;125(17):2597\u2013604.","journal-title":"Blood"},{"issue":"7","key":"2411_CR130","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1182\/blood-2015-09-618587","volume":"127","author":"MD Hoban","year":"2016","unstructured":"Hoban MD, Orkin SH, Bauer DE. Genetic treatment of a molecular disorder: gene therapy approaches to sickle cell disease. Blood. 2016;127(7):839\u201348.","journal-title":"Blood"},{"key":"2411_CR131","doi-asserted-by":"publisher","first-page":"7085","DOI":"10.1038\/ncomms8085","volume":"6","author":"B Wienert","year":"2015","unstructured":"Wienert B, Funnell AP, Norton LJ, Pearson RC, Wilkinson-White LE, Lester K, et al. Editing the genome to introduce a beneficial naturally occurring mutation associated with increased fetal globin. Nat Commun. 2015;6:7085.","journal-title":"Nat Commun"},{"issue":"6270","key":"2411_CR132","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1126\/science.aad3312","volume":"351","author":"T Masuda","year":"2016","unstructured":"Masuda T, Wang X, Maeda M, Canver MC, Sher F, Funnell AP, et al. Transcription factors LRF and BCL11A independently repress expression of fetal hemoglobin. Science. 2016;351(6270):285\u20139.","journal-title":"Science"},{"issue":"16","key":"2411_CR133","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1182\/blood-2015-06-649087","volume":"126","author":"A Renneville","year":"2015","unstructured":"Renneville A, Van Galen P, Canver MC, McConkey M, Krill-Burger JM, Dorfman DM, et al. EHMT1 and EHMT2 inhibition induces fetal hemoglobin expression. Blood. 2015;126(16):1930\u20139.","journal-title":"Blood"},{"issue":"2","key":"2411_CR134","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1089\/hum.2016.007","volume":"27","author":"O Negre","year":"2016","unstructured":"Negre O, Eggimann AV, Beuzard Y, Ribeil JA, Bourget P, Borwornpinyo S, et al. Gene therapy of the \u03b2-hemoglobinopathies by lentiviral transfer of the \u03b2A(T87Q)-Globin gene. Hum Gene Ther. 2016;27(2):148\u201365.","journal-title":"Hum Gene Ther"},{"issue":"s1","key":"2411_CR135","first-page":"59","volume":"102","author":"JA Ribeil","year":"2017","unstructured":"Ribeil JA, Cavazzana M, Touzot F, Payen E, Neven B, Lefrere F, et al. Clinical outcomes of gene therapy with BB305 lentiviral vector for sickle cell disease and \u03b2-thalassaemia. Haematologica. 2017;102(s1):59.","journal-title":"Haematologica"},{"key":"2411_CR136","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1196\/annals.1345.059","volume":"1054","author":"Z Pakbaz","year":"2005","unstructured":"Pakbaz Z, Treadwell M, Yamashita R, Quirolo K, Foote D, Quill L, et al. Quality of life in patients with thalassemia intermedia compared to thalassemia major. Ann N Y Acad Sci. 2005;1054:457\u201361.","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"2411_CR137","doi-asserted-by":"publisher","first-page":"e2012058","DOI":"10.4084\/mjhid.2012.058","volume":"4","author":"H Safizadeh","year":"2012","unstructured":"Safizadeh H, Farahmandinia Z, Nejad SS, Pourdamghan N, Araste M. Quality of life in patients with thalassemia major and intermedia in kerman-iran (I.R.). Mediterr J Hematol Infect Dis. 2012;4(1):e2012058.","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"1","key":"2411_CR138","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1111\/bjh.14381","volume":"176","author":"A Vitrano","year":"2017","unstructured":"Vitrano A, Calvaruso G, Lai E, Colletta G, Quota A, Gerardi C, et al. The era of comparable life expectancy between thalassaemia major and intermedia: is it time to revisit the major-intermedia dichotomy? Br J Haematol. 2017;176(1):124\u201330.","journal-title":"Br J Haematol"},{"issue":"4","key":"2411_CR139","doi-asserted-by":"publisher","first-page":"291","DOI":"10.2190\/PM.44.4.a","volume":"44","author":"B Khoury","year":"2012","unstructured":"Khoury B, Musallam KM, Abi-Habib R, Bazzi L, Ward ZA, Succar J, et al. Prevalence of depression and anxiety in adult patients with \u03b2-thalassemia major and intermedia. Int J Psychiatry Med. 2012;44(4):291\u2013303.","journal-title":"Int J Psychiatry Med"},{"issue":"1","key":"2411_CR140","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s12185-011-0985-6","volume":"95","author":"M Karimi","year":"2012","unstructured":"Karimi M, Haghpanah S, Farhadi A, Yanvarian M. Genotype-phenotype relationship of patients with \u03b2-thalassemia taking hydroxyurea: a 13-year experience in Iran. Int J Hematol. 2012;95(1):51\u20136.","journal-title":"Int J Hematol"},{"issue":"1","key":"2411_CR141","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/j.1600-0609.2011.01620.x","volume":"87","author":"H Amoozgar","year":"2011","unstructured":"Amoozgar H, Farhani N, Khodadadi N, Karimi M, Cheriki S. Comparative study of pulmonary circulation and myocardial function in patients with \u03b2-thalassemia intermedia with and without hydroxyurea, a case-control study. Eur J Haematol. 2011;87(1):61\u20137.","journal-title":"Eur J Haematol"},{"issue":"5","key":"2411_CR142","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1097\/MPH.0b013e31821b0770","volume":"33","author":"SH Ansari","year":"2011","unstructured":"Ansari SH, Shamsi TS, Ashraf M, Perveen K, Farzana T, Bohray M, et al. Efficacy of hydroxyurea in providing transfusion independence in \u03b2-thalassemia. J Pediatr Hematol Oncol. 2011;33(5):339\u201343.","journal-title":"J Pediatr Hematol Oncol"},{"issue":"3","key":"2411_CR143","doi-asserted-by":"publisher","first-page":"205","DOI":"10.3109\/08880011003639952","volume":"27","author":"M Karimi","year":"2010","unstructured":"Karimi M, Cohan N, Mousavizadeh K, Falahi MJ, Haghpanah S. Adverse effects of hydroxyurea in beta-thalassemia intermedia patients: 10\u00a0years\u2019 experience. Pediatr Hematol Oncol. 2010;27(3):205\u201311.","journal-title":"Pediatr Hematol Oncol"},{"issue":"5","key":"2411_CR144","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1111\/j.1365-2141.2010.08397.x","volume":"151","author":"P Rigano","year":"2010","unstructured":"Rigano P, Pecoraro A, Calzolari R, Troia A, Acusto S, Renada S, et al. Desensitization to hydroxycarbamide following long-term treatment of thalassaemia intermedia as observed in vivo and in primary erythroid cultures from treated patients. Br J Haematol. 2010;151(5):509\u201315.","journal-title":"Br J Haematol"},{"issue":"2","key":"2411_CR145","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1136\/jcp.2009.070391","volume":"63","author":"KY Italia","year":"2010","unstructured":"Italia KY, Jijina FF, Merchant R, Panjwani S, Nadkarni AH, Sawant PM, et al. ffect of hydroxyurea on the transfusion requirements in patients with severe HbE-beta-thalassaemia: a genotypic and phenotypic study. J Clin Pathol. 2010;63(2):147\u201350.","journal-title":"J Clin Pathol"},{"issue":"5","key":"2411_CR146","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1002\/ajh.21120","volume":"83","author":"A Koren","year":"2008","unstructured":"Koren A, Levin C, Dgany O, Kransnov T, Elhasid R, Zalman L, et al. Response to hydroxyurea therapy in beta-thalassemia. Am J Hematol. 2008;83(5):366\u201370.","journal-title":"Am J Hematol"},{"issue":"10","key":"2411_CR147","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1111\/j.1537-2995.2007.01399.x","volume":"47","author":"M Bradai","year":"2007","unstructured":"Bradai M, Pissard S, Abad MT, Dechartes A, Ribeil JA, Landais P, et al. Decreased transfusion needs associated with hydroxyurea therapy in Algerian patients with thalassemia major or intermedia. Transfusion. 2007;47(10):1830\u20136.","journal-title":"Transfusion"},{"issue":"1","key":"2411_CR148","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/j.1365-2141.2006.06002.x","volume":"133","author":"A Manusco","year":"2006","unstructured":"Manusco A, Maggio A, Renda D, Di Marzo R, Rigano P. Treatment with hydroxycarbamide for intermedia thalassaemia: decrease of efficacy in some patients during long-term follow up. Br J Haematol. 2006;133(1):105\u20136.","journal-title":"Br J Haematol"},{"issue":"7","key":"2411_CR149","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1097\/01.mph.0000174386.13109.28","volume":"27","author":"M Karimi","year":"2005","unstructured":"Karimi M, Darzi H, Yavarian M. Hematologic and clinical responses of thalassemia intermedia patients to hydroxyurea during 6\u00a0years of therapy in Iran. J Pediatr Hematol Oncol. 2005;27(7):380\u20135.","journal-title":"J Pediatr Hematol Oncol"},{"issue":"7","key":"2411_CR150","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s00277-005-1026-4","volume":"84","author":"A Dixit","year":"2005","unstructured":"Dixit A, Chatterjee TC, Mishra P, Choudhry DR, Mahapatra M, Tyagi S, et al. Hydroxyurea in thalassemia intermedia\u2014a promising therapy. Ann Hematol. 2005;84(7):441\u20136.","journal-title":"Ann Hematol"},{"issue":"4","key":"2411_CR151","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1182\/blood-2003-01-0117","volume":"102","author":"M Bradai","year":"2003","unstructured":"Bradai M, Abad MT, Pissard S, Lamraoui F, Skopinski L, de Maontalembert M. Hydroxyurea can eliminate transfusion requirements in children with severe beta-thalassemia. Blood. 2003;102(4):1529\u201330.","journal-title":"Blood"},{"issue":"Suppl 2","key":"2411_CR152","first-page":"316","volume":"2","author":"MR Gamberini","year":"2004","unstructured":"Gamberini MR, Fortini M, De Sanctis V. Paraplegia due to spinal cord compression by extramedullary erythropoietic tissue in a thalassaemia intermedia patient with gynecomastia secondary to cirrhosis: successful treatment with hydroxyurea. Pediatr Endocrinol Rev. 2004;2(Suppl 2):316\u20138.","journal-title":"Pediatr Endocrinol Rev"},{"issue":"3","key":"2411_CR153","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1034\/j.1600-0609.2003.00037.x","volume":"70","author":"EV Paula De","year":"2003","unstructured":"De Paula EV, Lima CSP, Arruda VR, Alberto FL, Saad ST, Costa FF. Long-term hydroxyurea therapy in beta-thalassaemia patients. Eur J Haematol. 2003;70(3):151\u20135.","journal-title":"Eur J Haematol"},{"issue":"6","key":"2411_CR154","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1034\/j.1600-0609.2000.9c165.x","volume":"64","author":"P Cianciulli","year":"2000","unstructured":"Cianciulli P, di Toritto TC, Sorrentino F, Sergiacomi L, Massa A, Amadori S. Hydroxyurea therapy in paraparesis and cauda equina syndrome due to extramedullary haematopoiesis in thalassaemia: improvement of clinical and haematological parameters. Eur J Haematol. 2000;64(6):426\u20139.","journal-title":"Eur J Haematol"},{"issue":"4","key":"2411_CR155","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1002\/(SICI)1096-8652(199912)62:4<221::AID-AJH4>3.0.CO;2-R","volume":"62","author":"C Hoppe","year":"1999","unstructured":"Hoppe C, Vichinsky E, Lewis B, Foote D, Styles L. Hydroxyurea and sodium phenylbutyrate therapy in thalassemia intermedia. Am J Hematol. 1999;62(4):221\u20137.","journal-title":"Am J Hematol"},{"issue":"4","key":"2411_CR156","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1159\/000077551","volume":"111","author":"A Chaidos","year":"2004","unstructured":"Chaidos A, Makis A, Hatzimichael E, Tsiara S, Gouva M, Tzouvara E, et al. Treatment of \u03b2-thalassemia patients with recombinant human erythropoietin: effect on transfusion requirements and soluble adhesion molecules. Acta Haematol. 2004;111(4):189\u201395.","journal-title":"Acta Haematol"},{"issue":"12","key":"2411_CR157","doi-asserted-by":"crossref","first-page":"3258","DOI":"10.1182\/blood.V80.12.3258.3258","volume":"80","author":"NF Olivieri","year":"1992","unstructured":"Olivieri NF, Freedman MH, Perrine SP, Dover GJ, Sheridan B, Essentine DL, et al. Trial of recombinant human erythropoietin: three patients with thalassemia intermedia. Blood. 1992;80(12):3258\u201360.","journal-title":"Blood"},{"issue":"1","key":"2411_CR158","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/j.1600-0609.1997.tb01405.x","volume":"58","author":"K Bourantas","year":"1997","unstructured":"Bourantas K, Economou G, Georgiou J. Administration of high doses of recombinant human erythropoietin to patients with \u03b2-thalassemia intermedia: a preliminary trial. Eur J Haematol. 1997;58(1):22\u20135.","journal-title":"Eur J Haematol"},{"issue":"6","key":"2411_CR159","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1093\/tropej\/42.6.330","volume":"42","author":"G Nisli","year":"1996","unstructured":"Nisli G, Kavakli K, Vergin C, Oztop S, Ceting\u00fcl N. Recombinant human erythropoietin trial in thalassemia intermedia. J Trop Pediatr. 1996;42(6):330\u20134.","journal-title":"J Trop Pediatr"},{"issue":"1","key":"2411_CR160","first-page":"37","volume":"81","author":"F Dore","year":"1996","unstructured":"Dore F, Bonfigli S, Gaviano E, Pardini S, Longinotti M. Serum transferrin receptor levels in patients with thalassemia intermedia during RHuEPO administration. Haematologica. 1996;81(1):37\u20139.","journal-title":"Haematologica"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-018-2411-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-018-2411-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-018-2411-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T18:36:23Z","timestamp":1693506983000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-018-2411-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,29]]},"references-count":160,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["2411"],"URL":"https:\/\/doi.org\/10.1007\/s12185-018-2411-9","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,29]]},"assertion":[{"value":"2 October 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}